2005 |
- October 1, Sumitomo Dainippon Pharma created.
|
2006 |
- AmBisome® (therapeutic agent for systemic fungal infection) launched in Japan.
|
2007 |
- The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd.
- Mid-term Business Plan (FY2007-FY2009) drawn up.
|
2008 |
- LONASEN® (atypical antipsychotic) launched in Japan.
- AVAPRO® (therapeutic agent for hypertension) launched in Japan.
|
2009 |
- TRERIEF® (Parkinson's disease drug) launched in Japan.
- Dainippon Sumitomo Pharma America Holdings, Inc. (currently, Sumitomo Pharma America, Inc.) established in the U.S. as a holding company.
- Acquired Sepracor Inc. (currently, Sumitomo Pharma America, Inc.), which became a wholly owned subsidiary of the U.S. holdings company.
|
2010 |
- MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched in Japan.
- Second Mid-term Business Plan (FY2010-FY2012) drawn up.
- Sepracor Inc. (currently, Sumitomo Pharma America, Inc.) and Dainippon Sumitomo Pharma America, Inc. merged.
- METGLUCO® (biguanide oral hypoglycemic) launched in Japan.
- Growth hormone business transferred.
- Animal Health Products business split off to establish DS Pharma Animal Health Co., Ltd.
|
2011 |
- LATUDA® (atypical antipsychotic) launched in the U.S. by Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.)
- SUREPOST® (rapid-acting insulin secretagogue) launched in Japan.
|
2012 |
- Acquired Boston Biomedical, Inc.
- Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.) acquired Elevation Pharmaceuticals, Inc.
- AIMIX® (therapeutic agent for hypertension) launched in Japan.
|
2013 |
- Sunovion Pharmaceuticals Asia Pacific Pte Ltd. (currently, Sumitomo Pharma Asia Pacific Pte. Ltd.) established as a subsidiary in Singapore.
- Third Mid-term Business Plan (FY2013-FY2017) drawn up.
- Boston Biomedical Pharma, Inc. established in the U.S. as a subsidiary focusing on sales of anti-cancer drugs.
|
2014 |
- Joint venture company, Sighregen Co., Ltd. established.
- Kobe Regenerative & Cellular Medicine Center (currently, Regenerative & Cellular Medicine Kobe Center) opened.
Regenerative & Cellular Medicine Kobe Center
- APTIOM® (antiepileptic) launched in the U.S. by Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.)
- LATUDA® (atypical antipsychotic) launched in the U.K. by Sunovion Pharmaceuticals Europe Ltd.
|
2015 |
- Started promotion of REMITCH® with indication for pruritus in chronic liver disease patients.
|
2016 |
- Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.) acquired Cynapsus Therapeutics Inc., a Canadian company.
- DS Pharma Promo Co., Ltd. (currently, Sumitomo Pharma Promo Co., Ltd.) established as a subsidiary for promoting authorized generics etc.
|
2017 |
- Acquired Tolero Pharmaceuticals, Inc.
- Boston Biomedical Pharma, Inc. integrated into its subsidiary Boston Biomedical, Inc. and corporate name changed to Boston Biomedical, Inc.
|
2018 |
- LONASEN® (atypical antipsychotic) launched in China by Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (currently, Sumitomo Pharma (Suzhou) Co., Ltd.)
- Manufacturing Plant for Regenerative Medicine & Cell Therapy (SMaRT) completed.
- LONHALA® MAGNAIR® (therapeutic agent for COPD) launched in the U.S. by Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.)
|
2019 |
- Reorganized product sites from 4 sites to 2 sites.
- The in-vitro diagnostics business of DS Pharma Biomedical Co., Ltd. is succeeded by a joint venture company and consolidated with DS Pharma Promo Co., Ltd. (currently, Sumitomo Pharma Promo Co., Ltd.)
- Established a subsidiary, Sumitomo Pharmaceuticals (Thailand) Co., Ltd. (currently, Sumitomo Pharma (Thailand) Co., Ltd.) in Thailand.
- Mid-term Business Plan 2022 (FY2018-FY2022) drawn up.
- RETHIO® (conditioning treatment prior to autologous hematopoietic stem cell transplantation) launched in Japan.
- Started sales of Equa® and EquMet® (therapeutic agent for type 2 diabates) in Japan.
- LATUDA® (atypical antipsychotic) launched in China by Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (currently, Sumitomo Pharma (Suzhou) Co., Ltd.)
- LONASEN® Tape (atypical antipsychotic) launched in Japan.
- With the signing of a strategic alliance agreement with Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma was established to hold shares of Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences.
|
2020 |
- LATUDA® (atypical antipsychotic) launched in Japan.
- Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. integrated and corporate name changed to Sumitomo Dainippon Pharma Oncology, Inc. (currently, Sumitomo Pharma America, Inc.)
- Joint venture company (S-RACMO Co., Ltd.) for CDMO Business in the field of Regenerative Medicine and Cell Therapy established.
- A subsidiary, Sumitomo Pharmaceuticals Taiwan Co., Ltd. (currently, Sumitomo Pharma Taiwan Co., Ltd.) established in Taiwan.
- KYNMOBI® launched in the U.S. by Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma America, Inc.)
|
2021 |
- ORGOVYX® (therapeutic agent for advanced prostate cancer) launched in the U.S. by Myovant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.)
- Sumitovant Biopharma Ltd. made Urovant Sciences Ltd., a U.S. consolidated subsidiary, its wholly-owned subsidiary.
- GEMTESA® (therapeutic agent for overactive bladder (OAB)) launched in the U.S. by Urovant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.)
- Transferred shares of Sunovion Pharmaceuticals Europe Ltd.
- MYFEMBREE® (therapeutic agent for uterine fibroids) launched in the U.S. by Myovant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.)
- TWYMEEG® (therapeutic agent for type 2 diabetes) launched in Japan.
- Entered into an agreement for joint development and commercialization in Psychiatry and Neurology area with Otsuka Pharmaceutical Co., Ltd.
- A subsidiary (Sumitomo Pharma Malaysia Sdn. Bhd.) established in Malaysia.
|
2022 |
- Sumitomo Dainippon Pharma Co., Ltd. changed its company name to Sumitomo Pharma Co., Ltd.
- RYTHYMIC® (cultured thymus tissue for pediatric congenital athymia) launched in the U.S. by Enzyvant Therapeutics Ltd. (currently, Sumitomo Pharma America, Inc.)
- Started promotion for Agalsidase Beta BS I.V. Infusion [JCR] (therapeutic agent for Fabry disease) in Japan.
|
2023 |
- Sumitomo Pharma Food & Chemical Co., Ltd. transferred.
- Sumitomo Pharma Animal Health Co., Ltd. transferred.
- Started co-promotion for IZCARGO® (recombinant therapeutic for mucopolysaccharidosis type II) in Japan.
- Mid-term Business Plan 2027 (FY2023-FY2027) drawn up.
- Combined Group companies in the U.S. and Sumitomo Pharma America, Inc. launched.
|
2024 |
- Entered into an amendment agreement for joint development and commercialization in Psychiatry and Neurology area with Otsuka Pharmaceutical Co., Ltd.
|